Table 2.
Factors associated with poor-compliance in subjects of total cohort and subgroup
| |
Total subjects at year 1 (n = 333) |
Subgroup subjects at year 2 (n = 174)a |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Risk factors |
n (%) |
Univariate analysis |
Multivariate analysis |
n (%) |
Univariate analysis |
Multivariate analysis |
||||
| OR 95% CI | p-value | OR 95% CI | p-value | OR 95% CI | p-value | OR 95% CI | p-value | |||
| Age |
|
1.03 (1.01-1.05) |
0.007 |
1.02 (0.99-1.05) |
0.132 |
|
0.97 (0.94-0.99) |
0.045 |
0.97 (0.94-1.01) |
0.100 |
| First prescribed by |
|
|
|
|
|
|
|
|
|
|
| Rheumatologist |
55 (34.6) |
1.0 (referent) |
|
1.0 (referent) |
|
24 (48.0) |
1.0 (referent) |
|
1.0 (referent) |
|
| Orthopedist |
64 (40.3) |
2.67 (1.58-4.53) |
0.000 |
2.30 (1.26-4.22) |
0.007 |
13 (26.0) |
1.38 (0.60-3.14) |
0.447 |
1.52 (0.58-3.96) |
0.394 |
| Others |
40 (25.2) |
1.19 (0.70-2.03) |
0.525 |
1.12 (0.62-2.05) |
0.709 |
13 (26.0) |
0.85 (0.39-1.86) |
0.679 |
0.86 (0.35-2.14) |
0.746 |
| DXA |
13 (8.2) |
0.52 (0.32-0.85) |
0.008 |
0.51 (0.28-0.93) |
0.029 |
17 (34.0) |
0.97 (0.49-1.94) |
0.932 |
0.94 (0.39-2.26) |
0.895 |
| Vertebroplasty |
5 (3.1) |
0.91 (0.27-3.04) |
0.877 |
0.59 (0.15-2.30) |
0.450 |
1 (2.0) |
0.49 (0.06-4.27) |
0.515 |
0.71 (0.07-7.08) |
0.769 |
| Fracture site |
|
|
|
|
|
|
|
|
|
|
| Spine fracture |
131 (82.4) |
1.40 (0.81-2.40) |
0.225 |
1.54 (0.45-5.29) |
0.489 |
36 (72.0) |
0.68 (0.32-1.45) |
0.320 |
0.37 (0.05-2.95) |
0.345 |
| Hip fracture |
27 (17.0) |
1.49 (0.81-2.76) |
0.204 |
1.21 (0.41-3.54) |
0.731 |
7 (14.0) |
1.28 (0.48-3.36) |
0.620 |
0.47 (0.06-3.50) |
0.457 |
| Others fracture |
13 (8.2) |
1.85 (0.75-4.58) |
0.185 |
1.88 (0.69-5.10) |
0.216 |
3 (6.0) |
1.52 (0.35-6.61) |
0.577 |
1.16 (0.22-6.23) |
0.863 |
| Tobacco useb |
1 (0.6) |
-- |
0.477 |
0.00 (0.00) |
1.000 |
0 (0) |
-- |
-- |
-- |
-- |
| Alcohol use |
1 (0.6) |
1.10 (0.07-17.65) |
0.949 |
0.00 (0.00) |
1.000 |
1 (2.0) |
4.09 (0.00) |
1.000 |
1.37 (0.00) |
1.000 |
| Malignancy |
11 (6.9) |
1.00 (0.43-2.34) |
0.994 |
0.98 (0.39-2.45) |
0.960 |
3 (6.0) |
0.82 (0.21-3.15) |
0.767 |
0.78 (0.19-3.27) |
0.734 |
| Cardiac disease |
32 (20.1) |
1.94 (1.06-3.56) |
0.032 |
1.87 (0.93-3.75) |
0.079 |
7 (14.0) |
1.39 (0.52-3.72) |
0.512 |
1.79 (0.58-5.49) |
0.311 |
| Respiratory disease |
19 (11.9) |
1.34 (0.66-2.71) |
0.413 |
1.22 (0.57-2.63) |
0.610 |
4 (8.0) |
0.81 (0.25-2.65) |
0.729 |
0.72 (0.20-2.56) |
0.611 |
| Neuropsychiatric disease |
30 (18.9) |
1.21 (0.69-2.14) |
0.505 |
0.89 (0.47-1.70) |
0.732 |
6 (12.0) |
0.63 (0.24-1.67) |
0.354 |
0.68 (0.23-2.02) |
0.485 |
| Chronic kidney disease |
12 (7.5) |
1.34 (0.56-3.19) |
0.509 |
1.35 (0.51-3.58) |
0.548 |
2 (4.0) |
0.60 (0.12-2.95) |
0.533 |
0.66 (0.12-3.62) |
0.636 |
| Endocrine/metabolic |
29 (18.2) |
1.54 (0.85-2.81) |
0.157 |
1.81 (0.90-3.64) |
0.095 |
6 (12.0) |
0.92 (0.34-2.51) |
0.871 |
0.82 (0.26-2.60) |
0.734 |
| Hypertension |
49 (30.8) |
0.83 (0.52-1.31) |
0.411 |
0.62 (0.37-1.06) |
0.083 |
21 (42.0) |
1.52 (0.77-2.99) |
0.224 |
1.62 (0.77-3.43) |
0.207 |
| Rheumatoid arthritis |
3 (1.9) |
0.22 (0.06-0.78) |
0.011 |
0.19 (0.04-0.81) |
0.025 |
4 (8.0) |
0.99 (0.30-3.32) |
0.989 |
0.81 (0.17-3.89) |
0.790 |
| Hepatobiliary disease |
6 (3.8) |
0.42 (0.16-1.10) |
0.075 |
0.44 (0.16-1.25) |
0.124 |
2 (4.0) |
0.36 (0.08-1.64) |
0.185 |
0.45 (0.09-2.33) |
0.340 |
| Steroid use | 21 (13.2) | 0.73 (0.40-1.34) | 0.307 | 1.48 (0.68-3.22) | 0.320 | 10 (20.0) | 1.30 (0.56-3.02) | 0.541 | 1.02 (0.31-3.29) | 0.980 |
OR odds ratio, CI confidence interval, Serum creatinine >1.4 mg/dl; aSubjects with MPR ≥ 80% at year 1; bNo one smoked, so the factor cannot be estimated; All comparisons denote present vs. absent.